Search

Dr. Gary Deng of the Integrative Medicine Service helps separate the hype from the proven health benefits of mushroom supplements.

… Tuesday, October 22, 2024 Mushrooms have always had an aura of special power about them. People all over the world have used them as medicine in the treatment of infection, lung disease, cancer, and other conditions for thousands of years. They have long been central to traditional medicine throughout

MSK Kids, the pediatric oncology program at MSK, is committed to shining a light on pediatric cancer. While there is a significant threat to pediatric cancer research stemming from COVID-19’s impact on philanthropy, several organizations helped MSK recognize pediatric cancer awareness month by fundraising for MSK Kids.

… Friday, October 16, 2020 MSK Kids, the pediatric oncology program at MSK, is committed to shining a light on pediatric cancer. Our clinicians and care teams are engaged in groundbreaking research that will continue to create tomorrow’s breakthroughs. While there is a significant threat to pediatric cancer

By switching from one cellular identity to another, lung cancer cells can evade targeted therapies. MSK scientists are trying to stop that from happening.

… Thursday, October 28, 2021 For people with lung cancer , drug resistance is the major cause of relapse. A tumor might respond very well at first — maybe even shrinking down to an undetectable level — only to develop resistance and grow back. Scientists are learning that one of the ways that lung cancers

Learn how genetic analysis of prostate cancer tumors is guiding treatment with checkpoint inhibitor immunotherapy.

… Friday, October 24, 2025 Immunotherapy drugs called  checkpoint inhibitors  are a promising cancer treatment, but so far only a minority of people respond to them. This has been especially notable in the treatment of  prostate cancer , the most common cancer in men, after skin cancer. Researchers at

Memorial Sloan Kettering researchers have found why certain drugs are not sufficiently effective in treating leukemias called myeloproliferative neoplasms.

… Thursday, September 6, 2012 Summary Memorial Sloan Kettering researchers have found why certain drugs are not sufficiently effective in treating leukemias called myeloproliferative neoplasms. Memorial Sloan Kettering researchers have discovered why a class of drugs called JAK2 inhibitors has not been

A pivotal international study published in the New England Journal of Medicine and led in part by José Baselga, MD, PhD, Physician-in-Chief at Memorial Sloan Kettering Cancer Center (MSK), offers proof of better treatment options for patients with HER2-positive early breast cancer. The new international research found that the drug pertuzumab (Perjeta®) significantly improved invasive-disease-free survival (IDFS) in patients with operable HER2-positive breast cancer when added to trastuzumab (Herceptin®) and chemotherapy. The findings of this study were presented at the American Society of Clinical Oncology annual meeting today in Chicago.

… Monday, June 5, 2017 A pivotal international study published in the New England Journal of Medicine and led in part by José Baselga, MD, PhD , Physician-in-Chief at Memorial Sloan Kettering Cancer Center (MSK), offers proof of better treatment options for patients with HER2-positive early breast cancer

MSK introduced its first new creative campaign in nearly two decades. The creative platform and campaign elements were developed and produced by MSK’s creative agency of record, Pereira & O’Dell New York.

… Tuesday, September 2, 2014 Memorial Sloan Kettering Cancer Center today introduced its first new creative campaign in nearly two decades: More Science. Less Fear. The creative platform and campaign elements were developed and produced by MSK’s creative agency of record, Pereira & O’Dell New York. MSK

Four summer students -- Jeannie Camarillo, Emily Grzybowski, Nathaniel Kim, and Daniel Triner -- were named 2010 Rubin and Sarah Shaps Scholars.

… Thursday, September 1, 2011 Four summer students are named Rubin and Sarah Shaps Scholars each summer. Students are selected on the basis of their outstanding undergraduate credentials and their performance in our summer program. Jeannie Camarillo, a junior majoring in physiology at the University of

MSK physicians and scientists are involved in notable research to be presented at the meeting and are available to comment on a variety of topics within leukemia, lymphoma, and multiple myeloma.

… Friday, December 4, 2020 Thousands of oncology experts from around the world will tune in December 5-8, 2020 for The American Society of Hematology’s (ASH) Annual Meeting and Exposition . For more than 60 years, the (ASH) Annual Meeting and Exposition has been the world’s most comprehensive hematology

MSK investigators report a new tool that may help them determine the origin of some metastatic tumors, potentially leading to better targeted treatments.

… Thursday, November 14, 2019 Summary Despite many advances in diagnostic technologies, the original site of some cancers will never be found. A new tool may help. Experts estimate that between 2 and 5% of all cancers are classified as cancer of unknown primary (CUP) , also called occult primary cancer